Johnson & Johnson (NYSE:JNJ) Posts Earnings Results, Beats Estimates By $0.06 EPS

Johnson & Johnson (NYSE:JNJ) released its quarterly earnings results on Wednesday. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06, FiscalAI reports. The company had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The firm’s revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.77 earnings per share. Johnson & Johnson updated its FY 2026 guidance to 11.600-11.750 EPS.

Here are the key takeaways from Johnson & Johnson’s conference call:

• Johnson & Johnson beat Q2 expectations and raised full-year guidance. Worldwide sales were $25.3 billion, operational growth was 5.6% despite a STELARA headwind, and management lifted 2026 operational sales growth and EPS targets.
• Innovative Medicine remained the main growth engine. Segment sales rose 6.8%, driven by strong oncology, immunology, and neuroscience performance, with standout growth from DARZALEX, TREMFYA, CAPLYTA, and new launches like ICOTYDE and INLEXZO.
• Several pipeline and launch programs are showing early momentum. Management said ICOTYDE has passed 10,000 patients, INLEXZO is reaching about one-third of eligible patients in the U.S., and new data at ASCO and elsewhere support longer-term growth in oncology and immunology.
• MedTech growth was solid overall, but cardiovascular was softer than expected. Q2 MedTech sales rose 3.6%, while electrophysiology faced China inventory headwinds and Abiomed was pressured by more cautious physician behavior after recent clinical data.
• Management expects second-half acceleration and highlighted multiple catalysts. The company cited upcoming FDA decisions and data readouts for products including IMAAVY, OTTAVA, VARIPULSE Pro, milvexian, and additional oncology programs, while also reiterating a path to double-digit growth by the end of the decade.

Johnson & Johnson Stock Up 1.1%

Shares of Johnson & Johnson stock opened at $249.70 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The stock has a market capitalization of $601.08 billion, a PE ratio of 28.93, a price-to-earnings-growth ratio of 2.34 and a beta of 0.24. Johnson & Johnson has a 52-week low of $162.30 and a 52-week high of $269.43. The company has a 50-day simple moving average of $239.19 and a two-hundred day simple moving average of $234.50.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Johnson & Johnson

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. boosted its stake in Johnson & Johnson by 84.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,900 shares of the company’s stock valued at $2,877,000 after purchasing an additional 6,364 shares during the last quarter. Strive Financial Group LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $199,000. Blue Sparrow LLC DE purchased a new position in Johnson & Johnson in the 4th quarter worth about $37,106,000. Mercer Global Advisors Inc. ADV grew its stake in shares of Johnson & Johnson by 10.8% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 849,734 shares of the company’s stock worth $167,341,000 after acquiring an additional 82,929 shares during the period. Finally, Summit Global Investments lifted its position in Johnson & Johnson by 3.8% during the fourth quarter. Summit Global Investments now owns 12,857 shares of the company’s stock valued at $2,661,000 after purchasing an additional 465 shares during the period. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on JNJ. Weiss Ratings cut shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, June 15th. Citigroup increased their price target on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Guggenheim lifted their price target on shares of Johnson & Johnson from $266.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, June 26th. Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Finally, TD Cowen raised their target price on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research note on Monday. Nineteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $265.30.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson beat second-quarter estimates, with EPS of $2.90 and revenue of $25.31 billion, helped by strong growth in Innovative Medicine and products like Darzalex, Tremfya, and Spravato. Article Title
• Positive Sentiment: The company raised its full-year 2026 guidance after the beat, signaling management sees continued momentum beyond its legacy drugs and improving demand across its pharma and medtech businesses. Article Title
• Positive Sentiment: Analysts and market commentary point to growing confidence in J&J’s pipeline, with upbeat conference-call takeaways suggesting momentum could carry into 2027. Article Title
• Positive Sentiment: Spravato sales surged, which also supports the broader view that J&J has growth opportunities in newer therapeutic areas, not just its older blockbuster drugs. Article Title
• Neutral Sentiment: The company declared its quarterly dividend, reinforcing its defensive income appeal for long-term holders. Article Title
• Negative Sentiment: Despite the beat and guidance hike, shares sold off in early trading as investors appeared to focus on slower overall profit growth, a slight MedTech miss, and the market’s high bar for large-cap healthcare names. Article Title
• Negative Sentiment: Some investors remain cautious because talc litigation and mixed MedTech execution continue to create uncertainty around the stock’s risk/reward profile. Article Title

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.